Morgan Stanley
PVLA

Morgan Stanley’s Palvella Therapeutics PVLA Stock Holding History

Morgan Stanley’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16M Sell
127,987
-92,675
-42% -$9.67M ﹤0.01% 3167
2025
Q4 		$23.1M Buy
220,662
+82,157
+59% +$7.01M ﹤0.01% 2800
2025
Q3 		$8.68M Buy
138,505
+2,751
+2% +$123K ﹤0.01% 3664
2025
Q2 		$3.06M Buy
135,754
+125,847
+1,270% +$2.95M ﹤0.01% 4433
2025
Q1 		$277K Buy
9,907
+9,816
+10,787% +$189K ﹤0.01% 5593
2024
Q4 		$1.09K Hold
91
– – ﹤0.01% 7262
2024
Q3 		$1.51K Buy
91
+9
+11% +$132 ﹤0.01% 7177
2024
Q2 		$805 Sell
82
-4
-5% -$45 ﹤0.01% 7179
2024
Q1 		$1.26K Sell
86
-85
-50% -$1.18K ﹤0.01% 7143
2023
Q4 		$2.5K Buy
171
+69
+68% +$1.26K ﹤0.01% 7109
2023
Q3 		$2.44K Hold
102
– – ﹤0.01% 7088
2023
Q2 		$1.36K Sell
102
-274
-73% -$16.6K ﹤0.01% 7253
2023
Q1 		$29.4K Sell
376
-2,347
-86% -$272K ﹤0.01% 6483
2022
Q4 		$227K Sell
2,723
-11,731
-81% -$943K ﹤0.01% 5615
2022
Q3 		$1.33M Sell
14,454
-151
-1% -$19.5K ﹤0.01% 4706
2022
Q2 		$2.19M Sell
14,605
-441
-3% -$80.5K ﹤0.01% 4459
2022
Q1 		$3.65M Sell
15,046
-2,110
-12% -$555K ﹤0.01% 4016
2021
Q4 		$5.19M Sell
17,156
-4,558
-21% -$1.46M ﹤0.01% 3684
2021
Q3 		$8.98M Buy
21,714
+764
+4% +$266K ﹤0.01% 3025
2021
Q2 		$6.42M Buy
20,950
+10,710
+105% +$2.35M ﹤0.01% 3510
2021
Q1 		$2.11M Sell
10,240
-447
-4% -$97.7K ﹤0.01% 4222
2020
Q4 		$2.14M Buy
10,687
+8,834
+477% +$1.84M ﹤0.01% 4097
2020
Q3 		$307K Buy
1,853
+1,039
+128% +$237K ﹤0.01% 4892
2020
Q2 		$202K Sell
814
-4,189
-84% -$980K ﹤0.01% 5073
2020
Q1 		$912K Sell
5,003
-5,137
-51% -$1.29M ﹤0.01% 4025
2019
Q4 		$2.94M Buy
10,140
+6,977
+221% +$1.93M ﹤0.01% 3720
2019
Q3 		$863K Buy
3,163
+2,854
+924% +$1.1M ﹤0.01% 4383
2019
Q2 		$117K Sell
309
-25
-7% -$7.46K ﹤0.01% 5254
2019
Q1 		$89K Sell
334
-1,020
-75% -$242K ﹤0.01% 5440
2018
Q4 		$288K Sell
1,354
-270
-17% -$83.8K ﹤0.01% 5119
2018
Q3 		$727K Buy
1,624
+45
+3% +$19.6K ﹤0.01% 4760
2018
Q2 		$641K Sell
1,579
-10,937
-87% -$5.2M ﹤0.01% 4931
2018
Q1 		$6.83M Buy
12,516
+9,181
+275% +$5.68M ﹤0.01% 2707
2017
Q4 		$2.01M Buy
3,335
+557
+20% +$259K ﹤0.01% 4022
2017
Q3 		$1.28M Sell
2,778
-504
-15% -$215K ﹤0.01% 4262
2017
Q2 		$1.33M Buy
3,282
+883
+37% +$258K ﹤0.01% 4159
2017
Q1 		$499K Buy
2,399
+122
+5% +$21.6K ﹤0.01% 4834
2016
Q4 		$256K Buy
2,277
+1,348
+145% +$167K ﹤0.01% 5255
2016
Q3 		$136K Buy
929
+928
+92,800% +$123K ﹤0.01% 5186
2016
Q2 		$0 Buy
+1
New +$153 ﹤0.01% 6679

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley's PVLA Position: Q1 2026 in Review

Morgan Stanley reduced its Palvella Therapeutics (PVLA) stake by 42% in Q1 2026, selling an estimated $9.67M and leaving 127,987 shares worth $16M. The position accounts for ﹤0.01% of the portfolio, ranked #3167.

Morgan Stanley first reported a position in PVLA in Q2 2016 and has held it in 40 quarters since. The position peaked at $23.1M in Q4 2025. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • Morgan Stanley held 127,987 shares of Palvella Therapeutics worth $16M as of Q1 2026.
  • Morgan Stanley sold 92,675 Palvella Therapeutics shares in Q1 2026, an estimated $9.67M.
  • Palvella Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #3167 holding.
  • Morgan Stanley first reported a position in Palvella Therapeutics in Q2 2016 and has held it in 40 quarters since.
  • Morgan Stanley's Palvella Therapeutics position peaked at $23.1M in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.